PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7808300

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	

CONVEYING PARTY DATA

Name	Execution Date
VERILY LIFE SCIENCES LLC	08/14/2020

RECEIVING PARTY DATA

Name:	TWENTY TWENTY THERAPEUTICS LLC		
Street Address:	259 EAST GRAND AVENUE		
City:	SOUTH SAN FRANCISCO		
State/Country:	CALIFORNIA		
Postal Code:	94080		

PROPERTY NUMBERS Total: 48

Property Type	Number
Application Number:	18059172
Application Number:	62790310
Application Number:	16736414
Application Number:	62790313
Application Number:	16736423
Application Number:	62686780
Application Number:	16444538
Application Number:	62847127
Application Number:	62822191
Application Number:	16819314
Application Number:	62824111
Application Number:	16829563
Application Number:	62824132
Application Number:	16829707
Application Number:	62819907
Application Number:	16820315
Application Number:	62847715
Application Number:	16872649
Application Number:	16871516
Application Number:	62847179

PATENT REEL: 062820 FRAME: 0978

507761166

Property Type	Number
Application Number:	62847576
Application Number:	15931563
Application Number:	62847593
Application Number:	15931241
Application Number:	62847693
Application Number:	15931482
Application Number:	63060363
Application Number:	63024373
Application Number:	62846428
Application Number:	62907848
Application Number:	62846443
Application Number:	63024725
PCT Number:	US2020012548
PCT Number:	US2020012552
PCT Number:	US2019037927
PCT Number:	US2020032510
PCT Number:	US2020023003
PCT Number:	US2020024906
PCT Number:	US2020024915
PCT Number:	US2020023195
PCT Number:	US2020032704
PCT Number:	US2020032425
PCT Number:	US2020032829
PCT Number:	US2020032798
PCT Number:	US2020032824
PCT Number:	US2020024209
PCT Number:	US2020024195
PCT Number:	US2020024201

CORRESPONDENCE DATA

Fax Number: (214)200-0853

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2146515000

Email: ipdocketing@haynesboone.com
Correspondent Name: HAYNES AND BOONE, LLP
Address Line 1: 2323 VICTORY AVENUE

Address Line 2: SUITE 700

Address Line 4: DALLAS, TEXAS 75219

ATTORNEY DOCKET NUMBER:	60430.22US02	
NAME OF SUBMITTER:	CLINT WILKINS	
SIGNATURE:	/Clint Wilkins/	
DATE SIGNED:	02/22/2023	
Total Attachments: 7		
source=60430.22US02_ Twenty Twenty Assignment#page1.tif		
source=60430.22US02_ Twenty Twenty Assignment#page2.tif		
source=60430.22US02_ Twenty Twenty Assignment#page3.tif		
source=60430.22US02_ Twenty Twenty Assignment#page4.tif		
source=60430.22US02_ Twenty Twenty Assignment#page5.tif		
source=60430.22US02_ Twenty Twenty Assignment#page6.tif		
source=60430.22US02_ Twenty Twenty Assignment#page7.tif		

CORPORATION TO CORPORATION ASSIGNMENT

This Corporation to Corporation Assignment (this "Assignment") is by:

Assignor:

VERILY LIFE SCIENCES LLC

Address:

269 East Grand Avenue

South San Francisco, CA 94080

a Delaware limited liability company

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment or operation of law, of the U.S., foreign and international patent applications and the U.S. and foreign patents identified in the attached **Schedule A** and the inventions covered thereby.

This Assignment is to:

Assignee:

TWENTY TWENTY THERAPEUTICS LLC

Address:

259 East Grand Avenue

South San Francisco, CA 94080

a Delaware limited liability company

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent applications and patents and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

- 1. Assignor hereby unconditionally and irrevocably assigns, conveys, transfers and sets over, to Assignee and its successors, legal representatives and assigns, Assignor's entire right, title and interest in, to and under the above-mentioned patent applications, patents and inventions, and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, national or regional stage entries of said international applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor, thereon or as a result thereof, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceedings, and any and all extensions of said letters patent or patents (collectively, the "Assigned Patents"), and all rights under the Paris Convention for the Protection of Industrial Property with respect to the Assigned Patents, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said patent applications and patents and any and all patent applications and patents claiming priority thereto or based thereon), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which said letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this Assignment not been made.
- 2. Assignor shall promptly sign and execute all papers and documents, and take all lawful oaths, necessary or appropriate for the procurement, maintenance, or defense of the Assigned Patents by, or otherwise to secure title thereto to, Assignee and its successors, legal representatives and assigns, at the sole cost and expense of Assignee and its successors, legal representatives and assigns. For purposes of this paragraph, "procurement, maintenance, or defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and defensive post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.
- 3. Assignor hereby authorizes and requests the Commissioner of Patents in the United States to issue the above mentioned letters patent of the United States to Assignee, and the counterpart thereof in each other applicable country and jurisdiction to issue the above mentioned patents of such other country or jurisdiction to Assignee, in each case as the assignee of said inventions for the sole use of Assignee and its successors, legal representatives and assigns.

- 4. Assignor hereby grants Assignee's attorneys, all of Haynes & Boone LLP, the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this Assignment, including the power to insert on this Assignment the application number and filing date of said applications when known.
- 5. This Assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one instrument.

[Signature pages follow]

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

VERILY LIFE SCIENCES LLC

Date: August 14, 2020

—Docusioned by: Andrew Conrad Signature:

Name: Andrew Conrad
Title: Chief Executive Officer

VERILY

44

[Signature Page to Corporation to Corporation Assignment]

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

We accept this Assignment:

ASSIGNEE:

TWENTY TWENTY THERAPEUTICS LLC

Date: August 14, 2020

Signature: Danie Aza

Title: Authorized Signatory

[Signature Page to Corporation to Corporation Assignment]

SCHEDULE A

		Filing	
Serial Number	Jurisdiction	Date	Title
<u> </u>	<u> </u>	Bute	PROGRAMMABLE THERAPEUTIC
			AGENT DELIVERY FROM EYE
62/790,310	US	1/9/2019	MOUNTED DEVICE
			PROGRAMMABLE THERAPEUTIC
			AGENT DELIVERY FROM EYE
16/736,414	US	1/7/2020	MOUNTED DEVICE
,			PROGRAMMABLE THERAPEUTIC
			AGENT DELIVERY FROM EYE
PCT/US2020/012548	PCT	1/7/2020	MOUNTED DEVICE
			EYE MOUNTED DEVICE FOR
62/790,313	US	1/9/2019	THERAPEUTIC AGENT RELEASE
			EYE MOUNTED DEVICE FOR
16/736,423	US	1/7/2020	THERAPEUTIC AGENT RELEASE
·			EYE MOUNTED DEVICE FOR
PCT/US2020/012552	PCT	1/7/2020	THERAPEUTIC AGENT RELEASE
			EYE-MOUNTABLE THERAPEUTIC
			DEVICES, AND ASSOCIATED
62/686,780	US	6/19/2018	SYSTEMS AND METHODS
			EYE-MOUNTABLE THERAPEUTIC
			DEVICES, AND ASSOCIATED
16/444,538	US	6/18/2019	SYSTEMS AND METHODS
			EYE-MOUNTABLE THERAPEUTIC
		1	DEVICES, AND ASSOCIATED
PCT/US19/37927	PCT	6/19/2019	SYSTEMS AND METHODS
			SYSTEMS, DEVICES AND METHODS
			FOR OPTICAL INTERROGATION OF
			AN IMPLANTABLE INTRAOCULAR
62/847,127	US	5/13/2019	PRESSURE SENSOR
			SYSTEMS, DEVICES AND METHODS
			FOR OPTICAL INTERROGATION OF
			AN IMPLANTABLE INTRAOCULAR
PCT/US2020/032510	PCT	5/12/2020	PRESSURE SENSOR
			IMAGING DEVICE FOR IDENTIFYING
62/822,191	US	3/22/2019	A LIQUID WITHIN A DISPENSER
			IMAGING DEVICE FOR IDENTIFYING
16/819,314	US	3/16/2020	A LIQUID WITHIN A DISPENSER
			IMAGING DEVICE FOR IDENTIFYING
PCT/US2020/023003	PCT	3/16/2020	A LIQUID WITHIN A DISPENSER
			Non-Invasive Periocular Device for Dry-
62/824,111	US	3/26/2019	Eye Treatment
16/829,563	US	3/25/2020	Non-Invasive Periocular Device for Dry-

			Eye Treatment
			Non-Invasive Periocular Device for Dry-
PCT/US2020/024906	PCT	3/26/2020	Eye Treatment
101/082020,021,000	101	3,20,2020	Non-Invasive Periocular Device for Dry-
			Eye Treatment and Closed-Loop Methods
62/824,132	US	3/26/2019	for Operating Same
		3/20/2019	Non-Invasive Periocular Device for Dry-
			Eye Treatment and Closed-Loop Methods
16/829,707	US	3/25/2020	for Operating Same
		0.20,2020	Non-Invasive Periocular Device for Dry-
			Eye Treatment and Closed-Loop Methods
PCT/US2020/024915	PCT	3/26/2020	for Operating Same
		012012020	JET PUMP FOR NONCONTACT
			TONOMETRY AND ASSOCIATED
62/819,907	US	3/18/2019	DEVICES, SYSTEMS, AND METHODS
		5/10/2019	JET PUMP FOR NONCONTACT
			TONOMETRY AND ASSOCIATED
16/820,315	US	3/16/2020	DEVICES, SYSTEMS, AND METHODS
		5,10,2020	JET PUMP FOR NONCONTACT
			TONOMETRY AND ASSOCIATED
PCT/US2020/023195	PCT	3/17/2020	DEVICES, SYSTEMS, AND METHODS
		0/1//2020	PERIOCULAR HUMIDITY
62/847,715	US	5/14/2019	MONITORING IN A HEADSET
			PERIOCULAR HUMIDITY
16/872,649	US	5/12/2020	MONITORING IN A HEADSET
			PERIOCULAR HUMIDITY
PCT/US2020/032704	PCT	5/13/2020	MONITORING IN A HEADSET
		-,.	DETECTING BACKSCATTER FROM
			DROPS DISPENSED FROM A
			HANDHELD DROPPER AND
			ASSOCIATED SYSTEMS, DEVICES,
16/871,516	US	5/11/2020	AND METHODS
			DETECTING BACKSCATTER FROM
			DROPS DISPENSED FROM A
			HANDHELD DROPPER AND
			ASSOCIATED SYSTEMS, DEVICES,
PCT/US2020/032425	PCT	5/12/2020	AND METHODS
			Using backscatter to detect drop dispensing
62/847,179	US	5/13/2019	from handheld medicine dropper
			THERAPEUTIC EYELID DEVICES
			AND METHODS FOR TREATING DRY
62/847,576	US	5/14/2019	EYE DISEASE
			THERAPEUTIC EYELID DEVICES
			AND METHODS FOR TREATING DRY
15/931,563	US	5/13/2020	EYE DISEASE
PCT/US2020/032829	PCT	5/14/2020	THERAPEUTIC EYELID DEVICES

			AND METHODS FOR TREATING DRY
			EYE DISEASE
			THERAPEUTIC DEVICES FOR
			PLACEMENT UNDERNEATH THE
			EYELID AND ASSOCIATED SYSTEMS
			AND METHODS FOR DRY EYE
62/847,593	US	5/14/2019	TREATMENT
02/017,333	- 05	3/11/2019	THERAPEUTIC DEVICES FOR
			PLACEMENT UNDERNEATH THE
			EYELID AND ASSOCIATED SYSTEMS
			AND METHODS FOR DRY EYE
15/931,241	US	5/13/2020	TREATMENT
13/731,241	OB	3/13/2020	THERAPEUTIC DEVICES FOR
			PLACEMENT UNDERNEATH THE
			EYELID AND ASSOCIATED SYSTEMS
PCT/US2020/032798	DCT	5/14/2020	AND METHODS FOR DRY EYE
PC1/US2020/032/98	PCT	5/14/2020	TREATMENT
62/947 602	TIC	5/14/2010	Viscous Micro Spray Device For
62/847,693	US	5/14/2019	Ophthalmic Applications
15/021 402	TIG	5/12/2020	Viscous Micro Spray Device For
15/931,482	US	5/13/2020	Ophthalmic Applications
TO CITE IX 1 CO O O O O O O O O O O	D.C.	5/14/2020	Viscous Micro Spray Device For
PCT/US2020/032824	PCT	5/14/2020	Ophthalmic Applications
<u> </u>			Smart contact lens to alleviate mild dry eye
			disease through corneal stimulation for
			reflex tearing of the Lacrimal gland to
63/060,363	US	8/3/2020	provide comfortable vision correction
			LED Arrangement for Ocular Microstream
63/024,373	US	5/13/2020	Targeting of the Eye
			Intraocular Micro-Display System with
62/846,428	US	5/10/2019	Intelligent Wireless Power Delivery
			Intraocular Micro-Display System with
PCT/US2020/024209	PCT	3/23/2020	Intelligent Wireless Power Delivery
			Intraocular Microdisplay Mechanical
			Interface preserving natural physio-optical
PCT/US2020/024195	PCT	3/23/2020	UX and Power Coupling
62/907,848	US	9/30/2019	Intraocular Microdisplay Optical System
PCT/US2020/024201	PCT	3/23/2020	Intraocular Microdisplay Optical System
62/846,443	US	5/10/2019	Intraocular Microdisplay Optical System
			Intravitreal injection device with combined
63/024,725	US	5/14/2020	vitreous sampling
		1 3/1 // 2/02/0	, 122 Can Dailibining

PATENT REEL: 062820 FRAME: 0987

RECORDED: 00/02/2020